{"entity":{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","aka":[],"tldr":"HER2 drugs can weaken the heart's pumping, usually reversibly, so heart function is checked every three months during treatment.","summary":"Asymptomatic LVEF decline in 10-15% and symptomatic heart failure in 1-4% with trastuzumab, higher with prior or concurrent anthracyclines (NSABP B-31: 4.1% vs 0.8%). Mechanism: HER2 signalling maintains cardiomyocyte survival under stress. Management: hold for LVEF drop ≥16 points or below normal, ACE inhibitors/beta-blockers, rechallenge after recovery; anthracycline-free regimens (TCHP, T-DXd neoadjuvant) reduce risk.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Trastuzumab","links":[{"label":"ClinicalTrials.gov NCT00712140: PERSEPHONE","url":"https://clinicaltrials.gov/study/NCT00712140"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["cardio-oncology"],"targets":[],"drugs":["trastuzumab","pertuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["persephone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Side effects"},"route":"/terms/trastuzumab-cardiotoxicity/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"},{"id":"cardiotoxicity-surveillance-recovery","kind":"technology","name":"Heart function after anthracyclines, trastuzumab and chest radiotherapy","route":"/technologies/cardiotoxicity-surveillance-recovery/"},{"id":"anthracycline-cardioprotection","kind":"technology","name":"Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors","route":"/technologies/anthracycline-cardioprotection/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"trial":[{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/"}],"bottleneck":[{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}]}}